Buprenorphine in the Treatment of Opioid Dependence

Special Treatment Populations: Pregnant Patients

Annitto WJ. Detoxification with buprenorphine of a pregnant heroin addict. American Journal on Addictions (9):92–93, 2000.

Barron S and Chung VM. Prenatal buprenorphine exposure and sexually dimorphic nonreproductive behaviors in rats. Pharmacology, Biochemistry, and Behavior (58):337–343, 1997.

Belcheva MM, Bohn LM, Ho MT, Johnson FE, Yanai J, Barron S, and Coscia CJ. Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine. Developmental Brain Research (111):35–42, 1998.

Belcheva MM, Dawn S, Barg J, McHale RJ, Ho MT, Ignatova E, and Coscia CJ. Transient down-regulation of neonatal rat brain-opioid receptors upon in utero exposure to buprenorphine. Developmental Brain Research (80):158–162, 1994.

Fischer G, Jagsch R, Eder H, Gombas W, Ethzersdorfer P, Schmidl-Mohl K, Schatten C, Weinger M, and Aschaure HN. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction (94):231–239, 1999.

Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M, Langer M, and Aschauer HN. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction (95):239–244, 2000.

Harper RG, Solish G, Feingold E, Gersten-Woolf NB, and Sokal MM. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. American Journal of Obstetrics and Gynecology (129):417–424, 1977.

Hirose M, Hosokawa T, and Tanaka Y. Extradural buprenorphine suppresses breast feeding after Caesarean section. British Journal of Anaesthesia (79):120–121, 1997.

Hutchings DE, Zmitrovich AC, Hamowy AS, and Liu PR. Prenatal administration of buprenorphine using the osmotic minipump: A preliminary study of maternal and offspring toxicity and growth in the rat. Neurotoxicology and Teratology (17):419–423, 1995.

Hutchings DE, Hamowy AS, Williams EM, and Zmitrovich AC. Prenatal administration of buprenorphine in the rat: Effects on the rest-activity cycle at 22 and 30 days of age. Pharmacology, Biochemistry, and Behavior (55):607–613, 1996.

Jarvis, MAE and Schnoll SH. Methadone treatment during pregnancy. Journal of Psychoactive Drugs (26)155–161, 1994.

Jernite M, Hadidallah F, Alt M, Alt R, Welsch M, Brettes JP, and Messer J. Subutex and pregnancy. Thérapie (53):180, 1998.

Johnson RE, Svikis DS, Kissin WB, Alpan J, Bienstock J, Cone EJ, Golden AS, Haug NA, Huggins GR, Jansson L, Lantz ME, Wilkins D, and Jasinski DR. Pilot open-label safety study of buprenorphine during pregnancy. In: Harris LS (ed.). Problems of Drug Dependence. NIDA Research Monograph, Number 179. Washington, DC: US Government Printing Office, 1998.

Jones HE, Velez ML, McCaul ME, and Svikis DS. Special treatment issues for women. In: Strain EC and Stitzer ML (eds.). Methadone Treatment for Opioid Dependence. Baltimore, MD: Johns Hopkins University Press, 1999, pp. 251–280.

Marquet P, Chevrel J, Lavignasse P, Merle L, and Lachâtre G. Buprenorphine withdrawal syndrome in a newborn. Clinical Pharmacology and Therapeutics (62):569–571, 1997.

Marquet P, Lavignasse P, Chevrel J, Lachtre G, and Merle L. In utero exposure to subutex induces no or mild withdrawal syndromes in the newborn. Thérapie (53):78, 1998.

Reisinger M. Treatment of four pregnant heroin addicts with buprenorphine: History and outcome. In: Harris LS (ed.). Problems of Drug Dependence. NIDA Research Monograph, Number 162. Washington, DC: US Government Printing Office, 1995.